Clinical Trials and Behavioral Studies

The Department of Psychiatry and Behavioral Sciences welcomes research participant’s from 12 to 70 years old to enroll in studies aimed at improving the diagnosis and treatment of schizophrenia, bipolar disorder, Alzheimer’s disease, depression, and anxiety.

We strive to reach out into the community in which we work to improve the public’s understanding of psychiatric illness, and to reduce the stigma that has been associated with mental illness in the past.

Each research group listed has multiple studies for you or a family member and you will be paid for your time.  Please call the telephone numbers listed below to learn how you can volunteer to be a research participant and help advance our understanding of psychiatric illness.

Clinical Research Program

The Clinical Research Program within the department helps Principle Investigators (PIs) and participants navigate the clinical research process. Learn more about our services, space, and meet our team.

Active Trials and Studies

Our current active protocols are listed below. If you have any questions about the particular study protocol, please contact the study coordinator.  

For general information about our research or participation, please call the Clinical Research Program office at 312-503-9100.

Trials
Chicago Adolescent Longitudinal Study
The purpose of this study is to evaluate young adults experiencing the initial symptoms of mental disorders. We hope this study will improve our understanding of how different brain areas work together and change over time in young adults experiencing these symp…
The purpose of this study is to evaluate young adults experiencing the initial symptoms of mental disorders. We hope this study will improve our understanding of how different brain areas work together and change over time in young adults experiencing these symptoms. Also, we want to see the effect of substance abuse and other environmental factors on the progression of mental disorders. Your part in this study will last for 2 years and involve 4 or more visits depending on your preference. Today’s visit will last approximately 30 minutes. Each of the following study visits will last about 4 hours. Overall, the study will take approximately 12 hours to complete.
Adolescents and young adults (ages 12 to 26 years old) with changes in thoughts, feelings, and behavior OR drug use.
Reilly, JamesReilly, James
  • Map it 680 N. Lake Shore Drive
    Chicago, IL
STU00055031
More Info

For more information on this study please contact us:

Fairchild, Melody Dawn 312 503 7071
Northwestern University The Department of Psychiatry and Behavioral Sciences, Clinical Research Program (NU CRP) Recruitment Pipeline
The recruitment pipeline provides research staff with an organized system of identifying research subjects.NU CRP clinical research studies covers a wide spectrum of …
The recruitment pipeline provides research staff with an organized system of identifying research subjects.NU CRP clinical research studies covers a wide spectrum of Axis I Diagnoses such as schizophrenia, depression, anxiety, etc. NU CRP also conducts research studies for patients who are diagnosed with certain neurological diseases such as Alzheimer’s disease, Tourette’s Syndrome, etc. NU CRP conducts basic, translational and clinical research. Personal Health Information (PHI) will not be collected. All information collected in this recruitment registry is based on the patient self-report. You will be contacted to answer additional questions by someone in the study staff and to determine your eligibility for the current studies.
Goldman, Morris BGoldman, Morris B
  • Map it 680 N. Lake Shore Drive
    Chicago, IL
STU00059328
More Info

For more information on this study please contact us:

Mihailovic, Marko 312 503 9100
Repetitive Transcranial Magnetic Stimulation in Breast Cancer Patients With Depression and Anxiety
The primary goals of this study are to determine if rTMS is safe and tolerable in depressed cancer patients and to determine how well these two methods of rTMS work in treating cancer-related depression…
The primary goals of this study are to determine if rTMS is safe and tolerable in depressed cancer patients and to determine how well these two methods of rTMS work in treating cancer-related depression. You are being asked to take part in this study because you are a cancer patient in remission who is depressed currently. In the future, we hope to be able to use rTMS on depressed cancer patients who are actively receiving cancer treatment. However, since this is a preliminary study, we will only include patients in remission. Finally, anxiety often accompanies depression. So, we are also interested in understanding your current level of anxiety and how rTMS affects any anxiety that you might have. Your participation in this study will last for approximately seven weeks and will involve 31 visits.
Dokucu, Mehmet EDokucu, Mehmet E
NCT01701284 STU00063218
More Info

For more information on this study please contact us:

Fairchild, Melody Dawn 312 503 7071
Mild Cognitive Impairment in Breast Cancer Patients
The purpose of this study is to improve our understanding of differences in size, shape and activity of a variety of brain areas that can occur in women with breast cancer undergoing adjuvant chemotherapy or hormonal therapy, and how these brain are…
The purpose of this study is to improve our understanding of differences in size, shape and activity of a variety of brain areas that can occur in women with breast cancer undergoing adjuvant chemotherapy or hormonal therapy, and how these brain areas are related to the development of mild cognitive impairment as the results of these treatments. This study involves obtaining pictures of the brain’s size, shape and activity using a Magnetic Resonance Imaging (MRI) device, a machine that uses a powerful magnet to obtain this information without using any radiation. This procedure has been used safely with humans in many different studies. Your part in this study will last for 1 to 2 years.
Female breast cancer patients between 40-70 years old
Wang, LeiWang, Lei
  • Map it 680 N. Lake Shore Drive
    Chicago, IL
NCT01949376 STU00069634
More Info

For more information on this study please contact us:

Berger, Jessica M 312 503 4995
Pregnant Women Taking Lamictal for Bipolar Disorder
This study seeks to examine how the dose of lamotrigine (Lamictal) should be adjusted during pregnancy for women with Bipolar Disorder. The investigators predict that the concentration of Lamictal in women's blood will de…
This study seeks to examine how the dose of lamotrigine (Lamictal) should be adjusted during pregnancy for women with Bipolar Disorder. The investigators predict that the concentration of Lamictal in women's blood will decrease during pregnancy, and increase after postpartum. Because the concentration of the medication is likely to decrease during pregnancy, it is important for doctors to know how much they should increase a patient's dose in order to prevent worsening of Bipolar symptoms. In this study, the investigators will ask that participants complete up to five overnight visits to our clinical research unit where their blood will be drawn every couple of hours, through an IV catheter, to measure how the concentration of lamotrigine (Lamictal) changes over time. Participants will be compensated for their time.
Clark, CrystalClark, Crystal
NCT01996293 STU00079810
More Info

For more information on this study please contact us:

1-855-NU-STUDY
NEUROLOGICAL MECHANISMS OF TREATMENT PROJECT (NMT): AN EXAMINATION OF THE NEUROLOGICAL EFFECTS OF COGNITIVE BEHAVIORAL THERAPY ON ADOLESCENTS WITH DEPRESSION
The purpose of this study is to see if Cognitive Behavioral Therapy changes the way the brains of adolescents with depression process informati…
The purpose of this study is to see if Cognitive Behavioral Therapy changes the way the brains of adolescents with depression process information. We hope to determine if adolescents with depression who have received treatment process information the way adolescents without depression react. Your child is being asked to participate in this study because he/she is age of 13-17 and has been diagnosed of Major Depressive Disorder (MDD). You or your child will be asked to complete 3 assessment days, including today, and 12 weeks of individual Cognitive Behavioral Therapy (CBT). During the assessment days, your child will be asked to complete questionnaires regarding how he/she is feeling and how he/she copes with stressful situations.
13-17 years old, diagnosed with Major Depressive Disorder
Breiter, HansBreiter, Hans
STU00081474
More Info

For more information on this study please contact us:

O'Dor, Sarah 312 503 1802
Effect of Magnesium Threonate (MgT) on Cognitive Enhancement in Schizophrenia
This study is being conducted in order to determine if an investigational drug, MMFS-202-302 improves mental function and are safe in people who have schizophrenia and are taking another medication for their illness. Menta…
This study is being conducted in order to determine if an investigational drug, MMFS-202-302 improves mental function and are safe in people who have schizophrenia and are taking another medication for their illness. Mental function is how your brain works and includes your memory and how you think and concentrate. An investigational drug is one that is not approved for sale by the US Food and Drug Administration (FDA) or any other regulatory or health agency. MMFS-202-302 has been self-affirmed by an expert panel convened by its manufacturer Magceutics as being produced using good manufacturing practices, and fulfilling the FDA’s criteria for GRAS (generally regarded as safe) status If you decide to participate, you will be in this study for up to 9 weeks (63 days) after the screening period. The screening period can last up to 2 weeks (14 days). The total length of your participation is up to 11 weeks (77 days). After the initial screening visit (Visit 1), you will be asked to return to the research site at least 5 more times to take part in additional study procedures.
18-55 years old, Diagnosis of Schizophrenia or Schizoaffective Disorder of at least 1 year
Meltzer, HerbertMeltzer, Herbert
NCT02237235 STU00098144
More Info

For more information on this study please contact us:

Wardell, Cale 312 503 9076
Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients
This study is being conducted in order to determine if an investigational drug, JNJ-18038683, improves mental function and is safe in people who have bipolar disorder and are taking othe…
This study is being conducted in order to determine if an investigational drug, JNJ-18038683, improves mental function and is safe in people who have bipolar disorder and are taking other medications for their illness. Mental function is how your brain works and includes your mood, memory and how you think and concentrate. An investigational drug is one that is not approved for sale by the US Food and Drug Administration (FDA) or any other regulatory or health agency. This study compares an experimental drug to a placebo. A placebo is an inactive substance made to look/taste like an active medicine. We expect that you will be in this research study for up to 10 weeks, including the screening period.
Adults 18 to 60 years old with diagnosis of of bipolar disorder
Meltzer, HerbertMeltzer, Herbert
  • Map it 680 N. Lake Shore Drive
    Chicago, IL
NCT02466685 STU00200919
More Info

For more information on this study please contact us:

Wardell, Cale 312 503 9076
Optimizing Medication Management for Mothers with Depression (OPTI-MOM)
The purpose of this study is to explore the way the antidepressant concentration (amount of medication) in the blood changes due to the physiological changes in the body (i.e., increased metabolism, hormones, and body fluid) dur…
The purpose of this study is to explore the way the antidepressant concentration (amount of medication) in the blood changes due to the physiological changes in the body (i.e., increased metabolism, hormones, and body fluid) during pregnancy and postpartum. Taking the same medication dose when you are pregnant may result in an amount of drug in your blood that is different than when you are not pregnant. We will also study the impact of genetic factors on the amount of drug in your blood. Drug metabolism (how medications are broken down, absorbed, and removed from the body) differs among people because of their unique genetic make-up, which can cause medications to be metabolized faster or slower. This means that when two people with different genetic backgrounds take the same dose, the concentration of the medicine in their blood can vary dramatically. . Changes in antidepressant concentrations are important to monitor, as decreases in drug levels may cause the antidepressant to become ineffective and result in an increase in mood symptoms or recurrence of depressive episodes. Increases in antidepressant concentration may lead to increased side effects. We are hoping to better understand the course of these changes across pregnancy and postpartum and how an individual’s genetic makeup impacts these changes. Our overall goal is to develop guidelines to optimize antidepressant treatment of pregnant women
Are 18 years of age or older
Are currently at or less than 18 weeks pregnant
Speak English
Have received a diagnosis of depression
Take sertraline (Zoloft), fluoxetine (Prozac), citalopram (Celexa), or escitalopram (Lexapro) and plan to continue it during pregnancy and postpartum
Wisner, KatherineWisner, Katherine
  • Map it 676 N. St. Clair Street
    Chicago, IL
NCT02519790 STU00201386
More Info

For more information on this study please contact us:

O'Shea, Kelly 312 695 6076
Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics
Medications for the treatment of schizophrenia come in varied forms. Some are taken one or more times a day; other types are taken once every 2 or…
Medications for the treatment of schizophrenia come in varied forms. Some are taken one or more times a day; other types are taken once every 2 or 4 weeks. The purpose of the PRELAPSE study is to compare standard treatment with treatment with a version of the medication aripiprazole that is taken only once each month. To allow the aripiprazole to be taken only once a month with current technology, the once monthly aripiprazole is given as an injection (sometimes called a “shot”). We expect that you will be in this research study for 24 months (two years). The study will last for approximately 3.If you choose to participate in the optional MRI sub-study, you will undergo up to 3 MRI sessions; one at the time of your baseline visit, a second that takes place coinciding with your Month 12 visit and a third at the Month 24 visit. Each appointment at the MRI facility should take approximately 1 hour.
Individuals with schizophrenia from 18 to 35 years old
Rado, JeffreyRado, Jeffrey
NCT02360319 STU00201898
More Info

For more information on this study please contact us:

Gagni, Germaine 312 503 9092